Literature DB >> 32839089

Microwave ablation versus radiofrequency ablation for perivascular hepatocellular carcinoma: a propensity score analysis.

Yuemin Feng1, Le Wang2, Huanran Lv3, Tongtong Shi4, Chenghui Xu4, Hang Zheng4, Jianni Qi5, Xinya Zhao6, Jie Li7, Yanjing Gao8, Chengyong Qin9, Qiang Zhu10.   

Abstract

BACKGROUND: To compare the efficacy and safety of microwave ablation (MWA) and radiofrequency ablation (RFA) as first-line treatments for perivascular HCC.
METHODS: This multicentre study enrolled 170 patients with perivascular HCC who underwent MWA or RFA. The ablation response, progression-free survival (PFS), overall survival (OS), and complications between the treatment groups for the total and propensity score-matched (PSM) cohorts were compared.
RESULTS: The disease control rates for MWA and RFA were similar in total (94% vs. 91%, p = 0.492) and PSM (93% vs. 93%, p = 1.00) cohorts. The PFS rates at 1, 3, and 5 years were 71%, 55% and 52% in MWA group and 61%, 33% and 28% in RFA group (p = 0.017). The OS rates were comparable between two groups in total (p = 0.249) and PSM cohorts (p = 0.345). In subgroup analyses, the PFS of patients with periportal HCC (45 vs. 36 months, p = 0.048) and a single HCC nodule (51 vs. 42 months, p = 0.014) were significantly better in MWA group than RFA. Major complications were more frequent in the MWA group than in RFA (27% vs. 7%, p < 0.001).
CONCLUSION: Compared with RFA, MWA provides better control of tumour progression especially in periportal HCC or single-nodule perivascular HCC patients.
Copyright © 2020 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32839089     DOI: 10.1016/j.hpb.2020.08.006

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  6 in total

1.  Local-Regional Treatment of Hepatocellular Carcinoma: A Primer for Radiologists.

Authors:  Natally Horvat; Ana I de Oliveira; Brunna Clemente de Oliveira; Jose A B Araujo-Filho; Maria El Homsi; Ahmed Elsakka; Raazi Bajwa; Guilherme L P Martins; Khaled M Elsayes; Marcos R Menezes
Journal:  Radiographics       Date:  2022-10       Impact factor: 6.312

2.  Efficacy of microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score analysis.

Authors:  Kanehiko Suwa; Toshihito Seki; Kazunori Aoi; Masao Yamashina; Miki Murata; Noriyo Yamashiki; Akiyoshi Nishio; Masaaki Shimatani; Makoto Naganuma
Journal:  Abdom Radiol (NY)       Date:  2021-03-06

Review 3.  Loco-Regional Treatments for Hepatocellular Carcinoma in People Living with HIV.

Authors:  Cristina Micali; Ylenia Russotto; Grazia Caci; Manuela Ceccarelli; Andrea Marino; Benedetto Maurizio Celesia; Giovanni Francesco Pellicanò; Giuseppe Nunnari; Emmanuele Venanzi Rullo
Journal:  Infect Dis Rep       Date:  2022-01-07

Review 4.  Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go.

Authors:  Kunpeng Wang; Cong Wang; Hao Jiang; Yaqiong Zhang; Weidong Lin; Jinggang Mo; Chong Jin
Journal:  Front Immunol       Date:  2021-12-15       Impact factor: 7.561

5.  Ten-Year Outcomes of Percutaneous Radiofrequency Ablation for Colorectal Cancer Liver Metastases in Perivascular vs. Non-Perivascular Locations: A Propensity-Score Matched Study.

Authors:  Binbin Jiang; Hongjie Luo; Kun Yan; Zhongyi Zhang; Xiaoting Li; Wei Wu; Wei Yang; Minhua Chen
Journal:  Front Oncol       Date:  2020-10-16       Impact factor: 6.244

6.  A Real-World Comparative Study of Microwave and Radiofrequency Ablation in Treatment-Naïve and Recurrent Hepatocellular Carcinoma.

Authors:  Soon Kyu Lee; Dong Jin Chung; Se Hyun Cho
Journal:  J Clin Med       Date:  2022-01-07       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.